The authors Erik S. Knudsen, PhD at Roswell Park Cancer Center, Geoffrey I. Shapiro, MD, PhD at Dana Farber Cancer Institute and Khandan Keyomarsi, PhD at MD Anderson conclude that: “These preliminary results highlight the potential for serum TK1 activity to act as a noninvasive biomarker for CDK4/6 inhibitor target engagement.” The authors also summarize the clinical trials that demonstrate the ability of DiviTum to identify CDK4/6 treatment resistance.

“It is very rewarding to receive this type of recognition from ASCO, the world's leading professional cancer organization. The authors state that DiviTum® can potentially be a tool for monitoring treatment effect of CDK4/6 inhibitors. I am thrilled that many years of clinical research by our team together with leading breast cancer clinicians has led to positive scientific review in a highly respected setting. We look forward to the results of ongoing clinical studies with DiviTum®,” said Anders Rylander, CEO of Biovica.

ASCO (American Society of Clinical Oncology) gathers cancer professionals across the world and has nearly 45,000 members. ASCO is the world's leading professional organization for physicians and oncology professionals caring for people with cancer. Every year in conjunction with the ASCO Annual Meeting, an educational book is issued addressing important topics in oncology.

Reference:
https://ascopubs.org/doi/full/10.1200/EDBK_281085